Department of Otolaryngology- Head and Neck Surgery, University of South Florida, Tampa, FL, United States of America.
Rhinology and Endoscopic Skull Base Program, Department of Otolaryngology- Head and Neck Surgery, University of Miami Miller School of Medicine, FL, United States of America.
Am J Otolaryngol. 2022 Jan-Feb;43(1):103214. doi: 10.1016/j.amjoto.2021.103214. Epub 2021 Sep 17.
Research indicates that most providers give opiates after endoscopic sinonasal surgery. The effectiveness of non-opiate medications after sinonasal surgery is poorly understood and most studies do not assess medication failure. This study compares oral opiate, oral opiate and topical steroid, and oral non-opiate pain control. Patient call-backs are used as a proxy for pain medication failure.
This study compares three medication regiments after sinonasal surgery for 180 adults with chronic rhinosinusitis. Patients were instructed to take acetaminophen for mild pain. For moderate/severe pain, patients used: 1) oxycodone-acetaminophen, 2) oxycodone-acetaminophen + budesonide nasal rinses, or 3) meloxicam + acetaminophen. Patients were instructed to call clinic if pain was not controlled. Descriptive statistics compared cohorts. Chi-square tests compared call-backs between cohorts. Logistic regression adjusted for baseline differences in covariates, comorbidities, and operative sites.
Cohorts had similar age, sex distribution, disease features, and extent of surgery. The meloxicam cohort had less subjects with pain disorders. The oxycodone cohort had less subjects with diabetes, septoplasty, and turbinate reduction. After adjusting for baseline differences and using oxycodone as the reference group (n = 50), the odds of calling clinic for poorly controlled pain was 0.18 (95% Confidence Interval (CI): 0.05-0.6) in the meloxicam cohort (n = 45) and 0.19 (95% CI:0.07-0.5) in the oxycodone + budesonide rinses cohort (n = 85).
In this study, both meloxicam and oxycodone + budesonide rinses were more effective at controlling pain after sinonasal surgery than oxycodone alone.
研究表明,大多数医生在鼻内镜鼻窦手术后会开阿片类药物。鼻内镜鼻窦手术后非阿片类药物的疗效知之甚少,大多数研究都没有评估药物治疗失败的情况。本研究比较了口服阿片类药物、口服阿片类药物加局部皮质类固醇和口服非阿片类药物的疼痛控制效果。患者回诊情况被用作疼痛药物治疗失败的替代指标。
本研究比较了 180 例慢性鼻-鼻窦炎成人患者在鼻内镜鼻窦手术后三种药物治疗方案。患者被指示服用对乙酰氨基酚治疗轻度疼痛。对于中度/重度疼痛,患者使用:1)羟考酮-对乙酰氨基酚,2)羟考酮-对乙酰氨基酚+布地奈德鼻腔冲洗,或 3)美洛昔康+对乙酰氨基酚。如果疼痛未得到控制,患者被指示到诊所就诊。描述性统计比较了队列。卡方检验比较了各队列间的回诊率。采用逻辑回归对基线协变量、合并症和手术部位的差异进行调整。
各队列的年龄、性别分布、疾病特征和手术范围相似。美洛昔康组中疼痛障碍患者较少。羟考酮组中糖尿病、鼻中隔成形术和鼻甲切除术患者较少。在调整了基线差异并以羟考酮为参照组(n=50)后,美洛昔康组(n=45)和羟考酮+布地奈德冲洗组(n=85)的疼痛控制不佳而回诊的可能性分别为 0.18(95%置信区间:0.05-0.6)和 0.19(95%置信区间:0.07-0.5)。
在本研究中,美洛昔康和羟考酮+布地奈德冲洗在鼻内镜鼻窦手术后控制疼痛方面均优于单独使用羟考酮。